Orkambi 125 mg

Orkambi 125 mg granules contain ivacaftor, a medication used to treat cystic fibrosis. This oral formulation helps manage symptoms and improve lung function in eligible patients.

Orkambi 125 mg granules are primarily used in the management of cystic fibrosis. Ivacaftor, the active ingredient, works to improve the function of a protein affected by the CFTR gene mutation. This medication is often prescribed as part of a comprehensive treatment plan to help manage symptoms and enhance lung function in individuals with specific genetic markers.

Common effects of Orkambi 125 mg granules may include gastrointestinal discomfort, such as abdominal pain or diarrhea. Some users may also experience headaches or dizziness. These effects vary among individuals and are not experienced by everyone taking the medication.

Orkambi 125 mg granules should be handled with care, ensuring proper storage and administration as directed. It is important to follow the prescribed dosage and consult a healthcare provider before starting or stopping the medication. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Orkambi 125 mg granules may interact with certain medications, including those metabolized by the liver's CYP3A4 enzyme. It is advisable to avoid grapefruit and grapefruit juice, as they can affect the metabolism of ivacaftor. Always consult a healthcare provider before combining Orkambi with other medications.